Full Press Release Details
BIOTECHNOLOGY LEADER
AND SURGEON DR. MATTHEW KLEIN JOINS CLEARPOINT NEURO BOARD OF DIRECTORS
IRVINE, CA, April 17,
2020 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed
to ClearPoint Neuro's Board of Directors effective immediately. Dr. Klein, Chief Development Officer of PTC Therapeutics,
Inc. ("PTC"), is a veteran biotechnology company executive with extensive experience in drug discovery and development,
and a board-certified surgeon. He succeeds Marcio Souza, who joined ClearPoint Neuro's Board as PTC's representative
in connection with PTC's May 2019 equity investment in ClearPoint Neuro. Mr. Souza, who resigned from his position as PTC's
Chief Operating Officer, as was announced by PTC on March 16, 2020, will remain on ClearPoint Neuro's Board as an independent
Prior to joining PTC,
Dr. Klein served in several executive positions with BioElectron Technology Corporation ("BioElectron"), most recently
as BioElectron's Chief Executive Officer and a Director prior to its acquisition by PTC in 2019. Dr. Klein has a BA from
the University of Pennsylvania, an MD from Yale University School of Medicine and an MS in epidemiology from the University of
Washington School of Public Health.
by the addition of Matt to our board and the contributions he will make to our company and culture," commented Joe Burnett,
President and CEO. "As a patient-centric company, adding an established physician, scientist and leader to our board will
improve our ability to evaluate new technologies and partnerships."
to be joining ClearPoint Neuro's Board and look forward to bringing my experience as a drug developer and a surgeon to help
the company continue its growth and to fulfill its incredibly important mission," said Dr. Klein.
Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most
complex neurological disorders with pinpoint accuracy. Applications of the Company's current product portfolio include deep-brain
stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint
Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the United States.
The Company's SmartFlow cannula is being used in partnership or evaluation with more than 20 individual
biologics and drug delivery companies in various stages from preclinical research to late stage regulatory trials. To date, more
than 3,500 cases have been performed and supported by the Company's field-based clinical specialist team which offers support
and services for our partners. For more information, please visit www.clearpointneuro.com.
herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of
the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as
management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within
the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed
in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from
sales of the Company's ClearPoint Neuro Navigation System products; the Company's ability to market, commercialize
and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products; and estimates regarding
the sufficiency of the Company's cash resources. More detailed information on these and additional factors that could affect
the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report
on Form 10-K for the year ended December 31, 2019, which has been filed with the Securities and Exchange Commission.
Harold A. Hurwitz, Chief Financial Officer
President, Marketing